Predicting Clinical Outcomes Using Molecular Biomarkers.
Predicting Clinical Outcomes Using Molecular Biomarkers.
复制标题
DOI：
10.4137/bic.s33380
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Burke HB
中科院分区：
文献类型：
--
作者：
Burke HB
在过去的20年里，生物标志物的数量呈指数级增长。在最后一次统计中，有768，259篇论文在PubMed.gov上直接与生物标志物相关。尽管这些论文中有许多声称报道了临床上有用的分子生物标志物，但目前很少有临床应用。这表明，未能正确理解，临床评估和利用分子生物标志物，阻止了他们在治疗中的广泛采用，在比较效益分析，并将其整合到个性化的患者结果预测临床决策和治疗。一个简单的，一般的方法来了解如何预测临床结果的风险，诊断和预后的分子生物标志物。在未来，分子生物标志物将推动风险、诊断和预后方面的进展，它们将成为强大的分子治疗的靶点，并将使治疗个性化和优化。此外，基于分子生物标志物的临床预测将在医生-患者互动期间显示在临床医生的屏幕上，它们将成为医生-患者共享决策的组成部分，并且它们将改善临床护理和患者结果。
Over the past 20 years, there has been an exponential increase in the number of biomarkers. At the last count, there were 768,259 papers indexed in PubMed.gov directly related to biomarkers. Although many of these papers claim to report clinically useful molecular biomarkers, embarrassingly few are currently in clinical use. It is suggested that a failure to properly understand, clinically assess, and utilize molecular biomarkers has prevented their widespread adoption in treatment, in comparative benefit analyses, and their integration into individualized patient outcome predictions for clinical decision-making and therapy. A straightforward, general approach to understanding how to predict clinical outcomes using risk, diagnostic, and prognostic molecular biomarkers is presented. In the future, molecular biomarkers will drive advances in risk, diagnosis, and prognosis, they will be the targets of powerful molecular therapies, and they will individualize and optimize therapy. Furthermore, clinical predictions based on molecular biomarkers will be displayed on the clinician’s screen during the physician–patient interaction, they will be an integral part of physician–patient-shared decision-making, and they will improve clinical care and patient outcomes.